Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Abbisko Cayman Limited ( (HK:2256) ).
Abbisko reported its annual results for 2025 alongside corporate governance changes, including the resignation of Dr. Yu Hongping and Ms. Chan Yin Wah as joint company secretaries and the appointment of Ms. Zhang Hanxi and Ms. Lin Sio Ngo as their replacements, with Ms. Lin also taking over as authorised representative and process agent. These moves leave Dr. Yu in his executive director and chief scientific officer roles, suggesting continuity in scientific leadership while refreshing compliance and administrative oversight.
Operationally, 2025 marked Abbisko’s transition toward commercial-stage status as China’s regulator approved its lead asset pimicotinib for adult tenosynovial giant cell tumor, the first CSF-1R inhibitor cleared in the country, with global commercialization handled by partner Merck KGaA. The company also secured U.S. FDA acceptance of a new drug application for pimicotinib and received a US$85 million option exercise payment from Merck, while advancing a registrational Phase III trial of its FGFR4 inhibitor irpagratinib in hepatocellular carcinoma across more than 50 sites in China, underscoring growing financial resources and a deepening late-stage oncology pipeline.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a Hong Kong–listed biopharmaceutical company focused on discovering and developing innovative small-molecule therapies. Its pipeline targets oncology and other serious diseases, with lead candidates such as pimicotinib and irpagratinib aimed at niche indications like tenosynovial giant cell tumor and hepatocellular carcinoma, often in collaboration with global partners.
Average Trading Volume: 1,513,671
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.64B
See more data about 2256 stock on TipRanks’ Stock Analysis page.